Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
 QUICK SEARCH:   [advanced]


     


Drug Monitoring and Toxicology

Citations 461-470 of 565 total displayed.

Past content (since Jan 1997):

TDM Conference
Prospective investigations of concentration–clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
Leslie M. Shaw, Bruce Kaplan, and Kenneth L. Brayman
Clin. Chem. 1998; 44: 381-387. [Abstract] [Full text] [PDF]  

TDM Conference
Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach
Yuen Yi Hon and William E. Evans
Clin. Chem. 1998; 44: 388-400. [Abstract] [Full text] [PDF]  

TDM Conference
Strategies for physician education in therapeutic drug monitoring
David W. Bates, Steven J. Soldin, Petrie M. Rainey, and Joseph N. Micelli
Clin. Chem. 1998; 44: 401-407. [Abstract] [Full text] [PDF]  

TDM Conference
Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies
Lutz Binder, Xaver Schiel, Claudia Binder, Cristina Fernandes Almeida Menke, Silke Schüttrumpf, Victor W. Armstrong, Michael Unterhalt, Norbert Erichsen, Wolfgang Hiddemann, and Michael Oellerich
Clin. Chem. 1998; 44: 408-414. [Abstract] [Full text] [PDF]  

TDM Conference
Therapeutic drug monitoring in special populations
Philip D. Walson
Clin. Chem. 1998; 44: 415-419. [Abstract] [Full text] [PDF]  

TDM Conference
Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
Ronald Lieberman, James A. Crowell, Ernest T. Hawk, Charles W. Boone, Caroline C. Sigman, and Gary J. Kelloff
Clin. Chem. 1998; 44: 420-427. [Abstract] [Full text] [PDF]  

TDM Conference
Pharmacodynamic monitoring of immunosuppressive drugs
Randall W. Yatscoff, Launa J. Aspeslet, and Heather L. Gallant
Clin. Chem. 1998; 44: 428-432. [Abstract] [Full text] [PDF]  

TDM Conference
Supporting pharmaceutical studies for FDA submissions: diversifying the drug monitoring laboratory
Thomas P. Moyer and Lawrence K. Oliver
Clin. Chem. 1998; 44: 433-436. [Abstract] [Full text] [PDF]  

Drug Monitoring and Toxicology
Study of arsenic–protein binding in serum of patients on continuous ambulatory peritoneal dialysis
Xinrong Zhang, Rita Cornelis, Jurgen De Kimpe, Louis Mees, and Norbert Lameire
Clin. Chem. 1998; 44: 141-147. [Abstract] [Full text] [PDF]  

General Clinical Chemistry
Mechanisms of dopamine and dobutamine interference in biochemical tests that use peroxide and peroxidase to generate chromophore
Brad S. Karon, Thomas M. Daly, and Mitchell G. Scott
Clin. Chem. 1998; 44: 155-160. [Abstract] [Full text] [PDF]  

[First page]   [Previous page]   [Next page]
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57

* Sign up for Collection Alerts

* Topical Collections Home

* Related collections:
 TOPIC AREAS
 Animal Clinical Chemistry
 Automation and Analytical Techniques
 Cancer Diagnostics (since 2002)
 Clinical Immunology
 Current Issues in Laboratory Medicine
 Drug Monitoring and Toxicology
 Endocrinology and Metabolism
 Evidence Based Laboratory Medicine and Test Utilization
 General Clinical Chemistry
 Heart Health and the Clinical Laboratory
 Hematology
 Hemostasis and Thrombosis
 Infectious Disease
 Informatics and Statistics
 Laboratory Management
 Lipids, Lipoproteins, and Cardiovascular Risk Factors
 Molecular Diagnostics and Genetics
 Nutrition
 Other Areas of Clinical Chemistry
 Pediatric Clinical Chemistry
 Point-of-Care Testing
 Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT
Copyright © 2009 by the American Association for Clinical Chemistry.